Latest News

Cambridge, Mass. — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. “We are delighted to have received this designation for TP-1287...
Mesalazine plus somatostatin and bifid triple viable capsules can effectively improve the clinical symptoms of patients with ulcerative colitis, according to a study in BMC Gastroenterology. Investigators sought to determine the effect of mesalazine plus somatostatin and bifid triple viable capsules on plasma inflammatory factors and T cell frequency in patients...
HONG KONG — Akeso Inc. announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab (开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XELOX) for first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ)...
CAMBRIDGE, Mass. – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial. GSK4381562 is a...
CAMBRIDGE, Mass. – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab...
A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don’t require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) presented their data today at the American...
Abstract Adolescent idiopathic scoliosis (AIS) is a three-dimensional growth disorder. Corrective surgical procedures are the recommended treatment option for a thoracic angle exceeding 50° and a lumbar major curve of 40°. Over the past few years, dynamic growth modulation implants have been developed as alternatives to permanent fusion. The ApiFix...
Zürich, Switzerland – People living with RMDs can now fill out the survey online, sharing their experiences to help build a comprehensive understanding of their disease’s impact. The data collected will be invaluable for researchers, healthcare professionals, and patients themselves, providing insights into the burden of RMDs and identifying areas...
KYLE — After learning that he had a second chance at life, Brandon Higgins wanted to contribute something great for his community. The Kyle resident contracted the rare Rocky Mountain Spotted Fever (RMSF), which is spread through the bite of an infected tick, in 2006 while he was a junior...